Published in Eur J Pharmacol on April 27, 1988
Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging (2005) 1.73
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A (1992) 1.68
Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol (2012) 1.49
MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) (2005) 1.35
Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One (2012) 1.25
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol (2012) 1.23
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) (2004) 1.22
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One (2012) 1.13
Contributions of serotonin in addiction vulnerability. Neuropharmacology (2011) 1.12
Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav Pharmacol (2008) 1.10
Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) (2004) 1.09
Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes. J Neuroimmunol (2007) 1.07
Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) (2004) 1.05
Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol (2003) 1.05
Impaired executive function in male MDMA ("ecstasy") users. Psychopharmacology (Berl) (2004) 1.00
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol (2008) 0.98
The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol (2010) 0.96
Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol (1999) 0.95
Ecstasy produces left ventricular dysfunction and oxidative stress in rats. Cardiovasc Res (2008) 0.94
Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. Br J Pharmacol (2001) 0.92
Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology (Berl) (2005) 0.91
Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl) (2005) 0.89
Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology (Berl) (2003) 0.89
Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors. Eur J Pharmacol (2006) 0.88
Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology (2007) 0.86
Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.85
Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br J Pharmacol (2005) 0.84
Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol (2009) 0.84
High-dose MDMA does not result in long-term changes in impulsivity in the rat. Psychopharmacology (Berl) (2006) 0.83
Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol (2007) 0.83
Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. J Neural Transm (Vienna) (1997) 0.82
Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys. Neuropharmacology (2011) 0.82
Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol (2011) 0.81
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Front Immunol (2015) 0.81
The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study. Horm Behav (2011) 0.81
Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart. Toxicol Sci (2015) 0.80
Effects of MDMA on body temperature in humans. Temperature (Austin) (2014) 0.80
3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture. Neuropharmacology (2008) 0.80
Ecstasy (3,4-methylenedioxymethamphetamine) limits murine gammaherpesvirus-68 induced monokine expression. Brain Behav Immun (2008) 0.80
Analysis of transcriptional responses in the mouse dorsal striatum following acute 3,4-methylenedioxymethamphetamine (ecstasy): identification of extracellular signal-regulated kinase-controlled genes. Neuroscience (2005) 0.79
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Initial deficit and recovery of function after MDMA preexposure in rats. Psychopharmacology (Berl) (2005) 0.77
MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology. Curr Neuropharmacol (2013) 0.76
Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists. Psychopharmacology (Berl) (2012) 0.76
Using 'hug drugs' to understand affiliative behavior: the value of the social neurochemistry perspective. Commentary on: 'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content by Wardle, Kirkpatrick, and de Wit (2014). Soc Cogn Affect Neurosci (2014) 0.75
Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells. PLoS One (2016) 0.75
The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology (Berl) (2016) 0.75
Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis). PLoS One (2016) 0.75
MDMA modulates spontaneous firing of subthalamic nucleus neurons in vitro. Exp Brain Res (2014) 0.75
Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci (1995) 3.04
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A (1995) 2.70
Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience (2007) 2.55
The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J Biol Chem (1986) 2.03
Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci (1985) 1.77
CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology (1995) 1.73
Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature (1995) 1.71
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci (1988) 1.52
Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci (1996) 1.40
Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology (1990) 1.33
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther (1987) 1.33
Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther (1985) 1.29
Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry (1996) 1.28
The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res (1997) 1.28
The ontogeny of brain receptors for corticotropin-releasing factor and the development of their functional association with adenylate cyclase. J Neurosci (1988) 1.27
Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci (1987) 1.24
Mapping second messenger systems in the brain: differential localizations of adenylate cyclase and protein kinase C. Proc Natl Acad Sci U S A (1986) 1.18
Interleukin 1 receptors in the brain and endocrine tissues. Immunol Today (1993) 1.18
MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav (1988) 1.17
Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol (1995) 1.15
Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal, and testis. Endocrinology (1985) 1.14
Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept (1997) 1.14
Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation. Gene (1999) 1.13
Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol (1997) 1.09
Stimulus-induced coordinate changes in mRNA abundance in single postsynaptic hippocampal CA1 neurons. Neuron (1992) 1.08
Corticotropin-releasing factor receptors in rat forebrain: autoradiographic identification. Science (1984) 1.06
Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature (1986) 1.05
Corticotropin-releasing factor receptors in mouse spleen: identification of receptor-bearing cells as resident macrophages. Endocrinology (1990) 1.05
In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J Neurosci (1992) 1.03
Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther (1990) 1.03
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem (1996) 1.03
Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology (1989) 1.01
Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci U S A (1998) 1.01
Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. Synapse (1987) 0.99
125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol (1996) 0.99
Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J Neuroimmunol (1996) 0.95
Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem (1997) 0.94
Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol Endocrinol (1997) 0.94
Heterogeneity between brain and pituitary corticotropin-releasing factor receptors is due to differential glycosylation. Endocrinology (1989) 0.93
Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology (1994) 0.92
Sigma receptors: from molecule to man. J Neurochem (1991) 0.92
Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology (1997) 0.91
3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther (1989) 0.90
Corticotropin-releasing factor receptors in mouse spleen: identification, autoradiographic localization, and regulation by divalent cations and guanine nucleotides. Endocrinology (1988) 0.90
Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology (1987) 0.90
Depletion of peripheral-type benzodiazepine receptors after hypophysectomy in rat adrenal gland and testis. Eur J Pharmacol (1985) 0.89
Brain corticotropin-releasing factor immunoreactivity and receptors in five inbred rat strains: relationship to forced swimming behaviour. Brain Res (1997) 0.89
Corticotropin-releasing factor mRNA is expressed in the inferior olives of rodents and primates. Brain Res (1986) 0.88
Characterization and regulation of corticotropin-releasing factor receptors in the central nervous, endocrine and immune systems. Ciba Found Symp (1993) 0.88
Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther (1991) 0.88
Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry (1991) 0.88
Corticotropin-releasing factor receptors: an overview. Exp Clin Endocrinol Diabetes (1997) 0.87
Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. J Pharmacol Exp Ther (1988) 0.86
Measurement of corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in human plasma by two-site enzyme-linked immunoabsorbant assay. J Clin Endocrinol Metab (1996) 0.86
Bone morphogenetic protein but not transforming growth factor-beta enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J Bone Joint Surg Am (1999) 0.86
Chronic cocaine administration alters corticotropin-releasing factor receptors in the rat brain. Brain Res (1990) 0.86
The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neuroreport (1998) 0.85
Reciprocal modulation of interleukin-1 beta (IL-1 beta) and IL-1 receptors by lipopolysaccharide (endotoxin) treatment in the mouse brain-endocrine-immune axis. Endocrinology (1993) 0.85
Neurotransmitter receptor mapping by autoradiography and other methods. Annu Rev Neurosci (1986) 0.85
Angiotensin-converting enzyme in the testis and epididymis: differential development and pituitary regulation of isozymes. Endocrinology (1985) 0.85
Brain serotonin and catecholamine responses to repeated stress in rats. Brain Res (1986) 0.84
Evidence for receptors specific for 17 beta-estradiol and testosterone in chondrocyte cultures. Connect Tissue Res (1994) 0.84
Matrix vesicles produced by osteoblast-like cells in culture become significantly enriched in proteoglycan-degrading metalloproteinases after addition of beta-glycerophosphate and ascorbic acid. Calcif Tissue Int (1994) 0.84
Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc Natl Acad Sci U S A (1996) 0.84
Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem (1996) 0.84
Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr (1989) 0.84
Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. Neuropsychopharmacology (1989) 0.83
Stress-induced inhibition of the plasma corticosterone response to a subsequent stress in rats: a nonadrenocorticotropin-mediated mechanism. Endocrinology (1982) 0.83
[125I]-labeled forskolin analogs which discriminate adenylyl cyclase and a glucose transporter: pharmacological characterization and localization of binding sites in rat brain by in vitro receptor autoradiography. J Pharmacol Exp Ther (1992) 0.83
Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol Appl Pharmacol (1989) 0.83
Angiotensin-converting enzyme localized in the rat pituitary and adrenal glands by [3H]captopril autoradiography. Endocrinology (1986) 0.83
Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J Pharmacol Exp Ther (1991) 0.83
Enhancement of performance in multiple learning tasks by corticotropin-releasing factor-binding protein ligand inhibitors. Peptides (1997) 0.83
Corticotropin-releasing factor receptors in human pituitary gland: autoradiographic localization. Neuroendocrinology (1985) 0.82
The brain corticotropin-releasing factor (CRF) receptor is of lower apparent molecular weight than the CRF receptor in anterior pituitary. Evidence from chemical cross-linking studies. J Biol Chem (1988) 0.82
Differential regulation of corticotropin-releasing factor receptors in anterior and intermediate lobes of pituitary and in brain following adrenalectomy in rats. Neurosci Lett (1985) 0.82
Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: methods and overview. Methods Enzymol (1986) 0.82
Corticotropin-releasing factor (CRF) receptors in intermediate lobe of the pituitary: biochemical characterization and autoradiographic localization. Peptides (1989) 0.82
Differential plasma beta-endorphin, beta-lipotropin, and adrenocorticotropin responses to stress in rats. Endocrinology (1985) 0.81
Interleukin-1 receptors: cloning studies and role in central nervous system disorders. Brain Res Brain Res Rev (1998) 0.81
Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites. Brain Res (1990) 0.81
Alterations in local cerebral glucose utilization following central administration of corticotropin-releasing factor in rats. Synapse (1989) 0.81
Culture surfaces coated with various implant materials affect chondrocyte growth and metabolism. J Orthop Res (1994) 0.80
Type I interleukin-1 receptors in the mouse brain-endocrine-immune axis labelled with [125I]recombinant human interleukin-1 receptor antagonist. J Neuroimmunol (1992) 0.80
Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur J Pharmacol (1995) 0.80
Corticotropin-releasing factor (CRF) receptors in infant rhesus monkey brain and pituitary gland: biochemical characterization and autoradiographic localization. Dev Neurosci (1995) 0.80
Regulation of interleukin-1 receptors and hypothalamic-pituitary-adrenal axis by lipopolysaccharide treatment in the mouse. Brain Res (1994) 0.80
Rat homolog of mouse interleukin-1 receptor accessory protein: cloning, localization and modulation studies. J Neuroimmunol (1996) 0.80
Lack of neurochemical evidence for neurotoxic effects of repeated cocaine administration in rats on brain monoamine neurons. Drug Alcohol Depend (1991) 0.80
Modulation of interleukin-1 receptors in the brain-endocrine-immune axis by stress and infection. Brain Behav Immun (1995) 0.80
[3H]opipramol labels a novel binding site and sigma receptors in rat brain membranes. Mol Pharmacol (1991) 0.80
Corticotropin-releasing factor receptor blockade enhances conditioned aversive properties of cocaine in rats. Psychopharmacology (Berl) (1998) 0.80
Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data. J Pharmacol Exp Ther (1990) 0.80
Differential effects of one and repeated endotoxin treatment on pituitary- adrenocortical hormones in the mouse: role of interleukin-1 and tumor necrosis factor-alpha. Neuroimmunomodulation (1999) 0.79
Distribution of corticotropin-releasing factor in the cerebellum and precerebellar nuclei of the opossum: a study utilizing immunohistochemistry, in situ hybridization histochemistry, and receptor autoradiography. J Comp Neurol (1989) 0.79
Effects of chronic stress on anterior pituitary and brain corticotropin-releasing factor receptors. Pharmacol Biochem Behav (1993) 0.79
Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervous system disorders. Baillieres Best Pract Res Clin Endocrinol Metab (1999) 0.79
Corticotropin-releasing factor (CRF) and interleukin-1 (IL-1) receptors in the brain-pituitary-immune axis. Psychopharmacol Bull (1989) 0.79
Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. Brain Res (1995) 0.79